相关实验视频
Updated: May 21, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
肥胖治疗的范式转变:对当前管道中药物的广泛审查
Ecesu Çetin1, Brian Pedersen1, Mehmet Furkan Burak1,2
1Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
新的肥胖药物,包括GLP-1类似物,可显著减肥并改善并发症. 新兴疗法针对肌肉的保存,代谢功能障碍和能源消耗,以更好地管理肥胖.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
- 公共卫生 公共卫生
背景情况:
- 肥胖是一个复杂的公共卫生挑战,随着治疗策略的不断发展.
- 最近代谢和和途径的进展缩小了药理和手术肥胖干预之间的差距.
- GLP-1模拟疗法可显著减肥,并改善与肥胖相关的并发症.
研究的目的:
- 审查当前的景观和未来的方向的抗肥胖药物.
- 突出肥胖症护理的未满足需求和各种治疗途径的必要性.
- 讨论新兴的候选药物,针对可持续体重管理的新机制.
主要方法:
- 关于肥胖治疗模式的最新发现的综述.
- 对当前和管道中的抗肥胖药物的分析.
- 讨论减肥方面的挑战,例如肌肉质量减轻和反弹体重增加.
主要成果:
- GLP-1模拟疗法提供与手术相比的减肥,并改善并发症.
- 管道中的药物包括肌酸激素抑制剂,氨酸激动剂,线粒体脱剂和NLRP-3抑制剂.
- 组合疗法 (双 / 三重激素激动剂) 旨在最大限度地减肥和耐受性.
结论:
- 新兴的抗肥胖药物为提高疗效和耐受性提供了新的机制.
- 未来的治疗方法旨在解决肌肉质量损失,代谢功能障碍 (MAFLD/MASH) 和提高能量消耗.
- 该管道有望为更可持续和个性化的肥胖管理策略提供希望.
更多相关视频
02:55Author Spotlight: Illuminating New Avenues for Adipose Tissue Metabolism and Disease Prevention
Published on: October 6, 2023
06:28A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
Published on: April 28, 2023
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hormonal Regulation
Oral Hypoglycemic Agents: Glinides
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Antidepressant Drugs: MAOIs and Other Agents